好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Adaptive Optics OCT Reveals Alterations in Macrophage-like Cell Morphology in Multiple Sclerosis
Neuro-ophthalmology/Neuro-otology
P5 - Poster Session 5 (11:45 AM-12:45 PM)
17-009

To apply adaptive optics-optical coherence tomography (AO-OCT) to investigate multiple sclerosis (MS)-induced changes in retinal macrophage-like cell (MLC) morphology and density.

We previously reported use of AO-OCT to visualize MLCs, which are presumed to be retinal microglia, at the vitreomacular interface in MS. Since microglia take on various morphologies in response to environmental conditions, including ramified, rod-like, and ameboid shapes, visualization of cell morphology with AO-OCT may enable direct quantification of the inflammatory and neurodegenerative state of retinal tissue in MS.

Six macular regions in one eye each from nine healthy volunteers (HV) and ten patients with MS (four with a history of optic neuritis (MS-ON) in the imaged eye, six without (MS-no-ON)) were imaged using AO-OCT on a custom-built multi-modal AO device. MLCs were examined directly above the inner limiting membrane (ILM) and labelled based on morphology.

Total MLC counts in the macular regions were higher in MS (median: MS=32.5, HV=6; p=0.033), preferentially in the temporal macula (median: MS=24.5, HV=4; p=0.007). Subtype analysis revealed higher rod-like (median: MS=3.5, HV=1; p=0.010) and ameboid (median: MS=18.5, HV=2; p=0.005) morphologies temporally in MS, along with higher ameboid (median: MS=9.5, HV=0; p=0.046) morphology nasally. There was no significant difference in ramified MLC count in any retinal location between MS and HV (median: MS=6, HV=1; p=0.322). The only difference between MS-ON and MS-no-ON was a higher rod-like appearance (median 12 vs 5, respectively, p=0.009).

Retinal MLCs in activated states are higher in MS as visualized by AO-OCT, particularly in the temporal macula. Our findings add further in vivo evidence of neurodegenerative changes in MS.

Authors/Disclosures
Sanjana S. Marikunte, MD (University of Maryland Medical School)
PRESENTER
Dr. Marikunte has nothing to disclose.
Xuemei Zeng, PhD Dr. Zeng has nothing to disclose.
Yan Liu, MSc Mr. Liu has received personal compensation for serving as an employee of Aeon biopharma. Mr. Liu has stock in Aeon Biopharma.
Daniel X. Hammer, PhD Dr. Hammer has received intellectual property interests from a discovery or technology relating to health care.
Daniel M. Harrison, MD, FAAN (University of Maryland School of Medicine) Dr. Harrison has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon Therapeutics. Dr. Harrison has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American College of Physicians. The institution of Dr. Harrison has received research support from Roche-Genentech. Dr. Harrison has received publishing royalties from a publication relating to health care.